Pharmacological Reviews xPharm- The Comprehensive Pharmacology Reference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Wolf, F. A.
Right arrow Articles by Brett, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Wolf, F. A.
Right arrow Articles by Brett, G. M.

Vol. 52, Issue 2, 207-236, June 2000

Ligand-Binding Proteins: Their Potential for Application in Systems for Controlled Delivery and Uptake of Ligands

Frits A. De Wolf1 and Gary M. Brett

Department of Bioconversion, Division Renewable Resources, Agrotechnological Research Institute (ATO), Wageningen University and Research Center, Wageningen, the Netherlands (F.A.d.W.); and Diet, Health and Consumer Sciences Division, Institute of Food Research, Norwich Research Park, Colney, Norwich, United Kingdom (G.M.B.)

I. Introduction: The Concept of Ligand-Selective Carrier Proteins
II. Survey of Ligand-Binding Protein Classes
    A. Biotin-Binding Proteins
    B. Lipid-Binding Proteins
    C. Periplasmic Binding Proteins
    D. Lectins
    E. Serum Albumins
    F. Immunoglobulins
    G. (Inactivated) Enzymes
    H. Other Protein Groups
        1. Insect Pheromone-Binding Proteins and Odorant-Binding Proteins.
        2. Immunosuppressant-Binding Proteins.
        3. Phosphate- and Sulfate-Binding Proteins.
    I. Comparative Overview of Protein Classes Surveyed in Section II
III. Discussion and Perspective
    A. Aspects Intrinsic to Ligand-Selective (High-Affinity) Binding Proteins
    B. Complex Systems Incorporating Ligand-Selective (High-Affinity) Binding Proteins
    C. Parameters That Influence the Choice of Specific Ligand-Binding Proteins
    D. Conclusion
IV. Summary
Acknowledgments
References

Unstable or harmful agents, such as drugs, vitamins, flavors, pheromones, and catalysts, for use in pharmaceutics, personal care, functional foods, crop protection, laboratories, offices, and industrial processes, require stabilization against oxidation and degradation or shielding from sensitive environments. Therefore, binding them to carriers with high affinity and selectivity for targeting to the right environment and subsequent controlled release is beneficial, especially if this allows improved control of (stimulus-induced) release. Proteins often possess one or more of these properties, whereas modern biotechnology and bioinformatics provide an increasing number of tools to engineer and adapt these properties. Carrier systems are now developed that incorporate proteins as the central ligand-binding component, e.g., lectins for glucose-triggered release of glycosylated insulin and bispecific antibodies for brain targeting of drugs, but ligand-binding proteins can potentially be used in many other applications. Collectively, the proteins available in nature bind an impressive variety of ligands and non-natural analogs. In this light, various ligand-binding protein classes are surveyed, including biotin-, lipid-, immunosuppressant-, insect pheromone-, phosphate-, and sulfate-binding proteins, as well as bacterial periplasmic proteins, lectins, serum albumins, immunoglobulins, and inactivated enzymes. Disadvantages, such as enzymatic degradation or immunogenicity, associated with the pharmaceutical use of certain proteins can be avoided by incorporating these proteins in more complex carrier and targeting systems. In other applications, this may not be necessary. The enclosure of high-affinity (potentially stimulus-sensitive) binding proteins within an envelope that acts as a diffusion barrier for the ligand may provide excellent slow release. Many possibilities seem to be as yet unexplored.


1 Address for correspondence: F. A. de Wolf, Department of Bioconversion, Division Renewable Resources, ATO, P.O. Box 17, 6700 AA Wageningen, the Netherlands. E-mail: f.a.dewolf{at}ato.dlo.nl


0031-6997/00/5202-0207$03.00/0
PHARMACOLOGICAL REVIEWS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Protein Sci.Home page
E. J. Choi, J. Mao, and S. L. Mayo
Computational design and biochemical characterization of maize nonspecific lipid transfer protein variants for biosensor applications
Protein Sci., April 1, 2007; 16(4): 582 - 588.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Hariharan, W. Liang, S.-H. Chou, and D.-H. Chin
A New Model for Ligand Release: ROLE OF SIDE CHAIN IN GATING THE ENEDIYNE ANTIBIOTIC
J. Biol. Chem., June 9, 2006; 281(23): 16025 - 16033.
[Abstract] [Full Text] [PDF]


Home page
Protein Sci.Home page
H.-C. Cheng, P.-T. Cheng, P. Peng, P.-C. Lyu, and Y.-J. Sun
Lipid binding in rice nonspecific lipid transfer protein-1 complexes from Oryza sativa
Protein Sci., September 1, 2004; 13(9): 2304 - 2315.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition